The Pre-Operative Evaluation Clinic: An Underutilized Service in Optimizing Analgesic Outcomes in Patients on Buprenorphine, Methadone, and Naltrexone for Substance Use Disorder or Chronic Pain
Addyson Sand,Tyler Powell,Helen Marry,Heather Rathbun,Jenna Steege,Allison LeMahieu,Adam Jacob,Ryan D'Souza,Oludare Olatoye
DOI: https://doi.org/10.2147/jpr.s471160
IF: 2.8319
2024-10-05
Journal of Pain Research
Abstract:Addyson E Sand, 1 Tyler E Powell, 1 Helen T Marry, 1 Heather R Rathbun, 1 Jenna R Steege, 1 Allison LeMahieu, 2 Adam K Jacob, 1 Ryan S D'Souza, 1 Oludare O Olatoye 1 1 Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA; 2 Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA Correspondence: Oludare O Olatoye, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA, Email Background: Patients receiving methadone, buprenorphine, and naltrexone for either chronic pain or substance use disorder (SUD) pose perioperative challenges. Due to their complex pharmacology, perioperative recommendations continue to evolve. Deviations from these recommendations may result in worse perioperative outcomes. A formal preoperative evaluation (POE) and optimization of patients on these medications are recommended to address these concerns. Methods: A single-center retrospective electronic health record review was performed with adult patients on methadone, buprenorphine, and naltrexone undergoing elective surgery between January 1, 2010 and December 31, 2020. The primary outcome of interest was the percentage of patients referred to the POE clinic for evaluation prior to the scheduled elective surgery. In addition, we assessed differences in variables (perioperative opioid, hospital length of stay, perioperative multimodal analgesics, perioperative complications, inpatient pain service consult, readmission within 30 days, cancellation of surgery, addiction medicine consult) based on POE clinic evaluation. This analysis was performed separately for patients prescribed these medications for SUD versus chronic pain. Continuous outcomes were analyzed using linear regression with generalized estimating equations (GEE) and robust variance estimates. Results: A total of 714 patients were included in the final analysis, of which 572 (80%) took buprenorphine, methadone, or naltrexone for chronic pain and 142 (20%) took these medications for SUD. Within the chronic pain and SUD subpopulations, 193 (34%) and 35 (25%) patients had formal POE clinic assessments, respectively. Among those taking these medications for chronic pain, POE clinic evaluation was associated with a higher likelihood for receiving non-opioid multimodal analgesics perioperatively (p = 0.016). Conclusion: Formal preoperative evaluations are currently underutilized in patients who take buprenorphine, methadone, or naltrexone for chronic pain or SUD. These patients may benefit from POE clinic assessment to optimize perioperative outcomes. Keywords: preoperative evaluation, chronic opioid therapy, substance use disorder, naltrexone, buprenorphine, methadone, perioperative pain management It is estimated that roughly 19.6 million Americans suffer from chronic pain that negatively impacts their quality of life and work. 1 Additionally, roughly 2.5 million in the United States have opioid use disorder (OUD) according to the 2020 National Survey on Drug Use and Health, and incident prescription opioid use also continues to remain high. 2,3 Buprenorphine, methadone, and naltrexone are approved by the US Food and Drug Administration (FDA) for the treatment of OUD. 4 These medications are also used in the management of refractory chronic pain and for the treatment of alcohol use disorder. The various indications of these medications are dependent on dose and frequency of use given differences in pharmacodynamics. Given the unique pharmacology of these three medications along with evolving perioperative recommendations, patients who take these medications for either chronic pain or substance use disorder (SUD) often require special perioperative considerations to ensure adequate management of acute pain and minimize withdrawal and relapse. 4–7 It is currently recommended that patients maintain methadone and buprenorphine which are mu-opioid receptor agonists while discontinuing naltrexone, a mu-opioid receptor antagonist, in the perioperative period. More importantly, multimodal analgesia is highly recommended for patients on these medications for adequate pain control and relapse prevention. 4,8 Further, a substantial portion of surgeons and anesthesiologists report discomfort or unfamiliarity with caring for patients who take these medications. 9–11 It is therefore imperative that these patients are identified and optimized preoperatively to limit adverse perioperative outcomes. It has been shown that Preoperative Evaluation (POE) Clinics may lead to improved perioperative outcomes by decreasing same-day -Abstract Truncated-
clinical neurology